Ecog-acrin Cancer Research Group

This study is for people with HER2-positive stage II to IIIa breast cancer whose tumors completely disappear after initial chemotherapy and targeted therapy before surgery. The goal is to see if using fewer chemotherapy drugs after surgery can still keep the cancer from coming ba…

This phase 3 trial tests whether adding darolutamide to standard hormone therapy (ADT) after prostate removal surgery can better prevent cancer from spreading in men with high-risk prostate cancer. The study enrolls 27 men who had their prostate removed and are at highest risk of…

This phase II trial compares two chemotherapy regimens in 176 older patients with metastatic pancreatic cancer. One group receives gemcitabine plus nab-paclitaxel, the other receives fluorouracil, leucovorin, and liposomal irinotecan. The goal is to see which combination helps pa…

This Phase III trial tests whether giving a highly targeted form of radiation (SAbR) before standard therapy (immunotherapy or targeted pills) helps people with kidney cancer that has spread to 2-5 spots in the body live longer. About 472 participants are randomly assigned to rec…

This phase II trial tests whether green tea catechins (GTC) can prevent low-risk prostate cancer from progressing in men on active surveillance. 360 participants will receive either GTC or a placebo daily. The study measures changes in a tumor growth marker (Ki-67) in biopsy samp…

This study tests whether a combination of two chemotherapy drugs (gemcitabine and docetaxel, or GEMDOCE) works as well as the standard BCG treatment for people with a high-grade, non-muscle invasive bladder cancer that hasn't been treated before. About 870 adults will be randomly…

This study tests three different chemotherapy combinations in people aged 70 or younger with newly diagnosed mantle cell lymphoma, a type of blood cancer. The goal is to see if adding a targeted drug called acalabrutinib to standard chemo improves how well the cancer responds. Ar…

This study looks at whether giving chemotherapy both before and after surgery helps people with stage II-III gallbladder cancer live longer compared to the usual approach of only giving chemo after surgery. About 186 participants will be randomly assigned to one of two groups. Th…

This study tests whether a stem cell transplant followed by the drug rituximab works better than rituximab alone for people with mantle cell lymphoma whose cancer is in first complete remission. About 689 adults aged 18 to 70 are taking part. The goal is to see which approach hel…

This phase II trial tests whether intensive blood pressure management (targeting systolic BP below 120 mmHg) is better than standard care (below 140 mmHg) for patients with advanced kidney or thyroid cancer starting anti-angiogenic TKI therapy. The study enrolls 61 participants a…

This phase II trial is testing whether a lower dose of chemotherapy plus radiation can work as well as the standard dose for early-stage anal cancer. The study includes 252 adults with T1-2N0M0 anal cancer. The goal is to see if the gentler approach controls the disease while imp…

This phase III trial compares the standard immunotherapy drug pembrolizumab alone versus pembrolizumab plus radiation therapy in 290 patients with metastatic head and neck cancer. The goal is to see if adding radiation improves overall survival. Participants receive pembrolizumab…

This study looks at whether doctors can safely stop standard anti-PD-1 immunotherapy early in people with advanced melanoma that cannot be surgically removed. By using PET/CT scans and tumor biopsies as guides, the goal is to reduce treatment side effects and burden without harmi…

This phase III trial is testing whether adding radiotherapy to standard chemotherapy improves survival in patients with HER2 negative esophageal or gastric cancer that has spread to a few other spots in the body (oligometastatic). About 314 participants will receive either chemot…

This study tests whether adding the immunotherapy drug pembrolizumab to standard tyrosine kinase inhibitors (TKIs) can eliminate tiny amounts of leftover leukemia cells in people with chronic myeloid leukemia (CML). About 40 adults with CML who still have detectable cancer marker…

This phase 2 trial tests whether adding the chemotherapy cabazitaxel to standard hormone therapy (abiraterone) can better control advanced prostate cancer that has spread and stopped responding to initial treatment. The study involves 223 men whose cancer progressed after docetax…

This study tests whether platinum-based chemotherapy (cisplatin or carboplatin) works better than capecitabine in people with a certain type of triple-negative breast cancer that remains after initial chemotherapy and surgery. About 415 participants with stage II-III breast cance…

This study tests a combination of two drugs—venetoclax and vincristine—in people with T-cell or B-cell acute lymphoblastic leukemia that has returned or not responded to prior treatment. The goal is to find the safest dose and see if the combo can lead to remission. About 40 adul…

This study tested a simplified care plan for people with acute promyelocytic leukemia (APL), a rare blood cancer. The goal was to see if following easy-to-use guidelines and getting support from APL experts could lower the number of deaths soon after starting treatment. About 200…

This phase 2 trial tested whether a combination of temozolomide and capecitabine works better than the standard cisplatin and etoposide for people with advanced, hard-to-treat gastrointestinal neuroendocrine carcinomas. The study enrolled 67 participants whose cancer had spread o…

This study looks at people with HPV-positive throat cancer that has spread but can still be removed with surgery. After surgery, some patients get the usual high-dose radiation plus chemo, while others get a lower dose. The goal is to see if the lower dose works just as well and …

This study tested whether adding capecitabine to the chemotherapy drug temozolomide helps people with advanced pancreatic neuroendocrine tumors live longer without their cancer growing. A total of 144 adults with tumors that could not be removed by surgery took part. The goal was…

This study looked at whether giving high-dose interferon alfa-2b for four weeks after melanoma surgery helps keep the cancer from returning. About 1,150 people with stage II or III melanoma that was completely removed took part. Half got the drug and half were simply watched. The…

This phase 3 trial tests whether the drug crizotinib can improve survival in people with early-stage non-small cell lung cancer that has a specific genetic change called ALK fusion. After surgery to remove the tumor, patients either take crizotinib pills or are simply observed. T…

This phase 3 trial compares two drug combinations—VRd and CRd—in over 1,000 people newly diagnosed with multiple myeloma. Both combos include lenalidomide and dexamethasone, plus either bortezomib or carfilzomib. After initial treatment, patients receive lenalidomide maintenance …

This study looks at whether a special type of MRI, called multiparametric MRI, can more accurately determine the stage of prostate cancer in people who are newly diagnosed and planning surgery. The goal is to see if this imaging method helps doctors find aggressive cancers and ma…

This phase 2 trial tests whether a special PET/CT scan using a radioactive tracer (FDG) can predict how well HER2-positive breast cancer responds to standard chemotherapy before surgery. About 235 patients with stage II-III HER2+ breast cancer will get the scan early in treatment…

This study tests whether a quick, low-cost breast MRI (about 10 minutes) finds cancer better than standard 3D mammography in women with dense breast tissue. Over 1,500 women without symptoms took part. The goal is to see which method catches more invasive cancers early, potential…

This phase 3 trial is comparing two types of mammograms—standard 2D digital mammography and newer 3D tomosynthesis—to see which is better at finding advanced breast cancers early. Over 108,000 women are taking part, and researchers will track cancer diagnoses over 4.5 years. The …

This phase 2 trial is testing whether a special type of PET/CT scan (FDG-PET/CT) can better measure how breast cancer that has spread to the bones responds to treatment. The study involves 138 participants with hormone receptor-positive metastatic breast cancer that is mostly in …

This study tests whether a special MRI scan, called DSC-MRI, can measure blood flow changes in brain tumors to predict if the drug bevacizumab is working early in treatment. Researchers will scan 146 patients with recurrent glioblastoma before and two weeks after starting the dru…

This study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…

This study tested a program to help cancer patients understand their fertility risks and get the right care. It included 434 women aged 15-55 with a new cancer diagnosis. The program aimed to connect them with specialists for pregnancy planning or fertility preservation based on …

This study looks at whether certain genes make African American women with breast cancer more likely to develop nerve damage (pain, numbness, tingling) from common chemotherapy drugs called taxanes. About 249 women with stage I-III breast cancer will receive either docetaxel or w…

This study follows 565 people with stage I-III colon or rectal cancer to understand how treatment affects their finances and quality of life. Participants complete surveys about costs and financial well-being over 12 months. The goal is to help doctors better support patients fac…

This study looks at whether combining MRI scans with genetic testing can help doctors choose the best treatment for people with ductal carcinoma in situ (DCIS), a very early form of breast cancer that hasn't spread. About 368 participants will have an MRI and a genetic test on th…